| BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting N Dagan, N Barda, E Kepten, O Miron, S Perchik, MA Katz, MA Hernán, ... New England Journal of Medicine 384 (15), 1412-1423, 2021 | 2669 | 2021 |
| Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting N Barda, N Dagan, Y Ben-Shlomo, E Kepten, J Waxman, R Ohana, ... New England Journal of Medicine, 2021 | 956 | 2021 |
| Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study N Barda, N Dagan, C Cohen, MA Hernán, M Lipsitch, IS Kohane, BY Reis, ... The Lancet 398 (10316), 2093-2100, 2021 | 877 | 2021 |
| Prediction of acute myeloid leukaemia risk in healthy individuals S Abelson, G Collord, SWK Ng, O Weissbrod, N Mendelson Cohen, ... Nature 559 (7714), 400-404, 2018 | 769 | 2018 |
| Myocarditis after Covid-19 vaccination in a large health care organization G Witberg, N Barda, S Hoss, I Richter, M Wiessman, Y Aviv, T Grinberg, ... New England Journal of Medicine 385 (23), 2132-2139, 2021 | 598 | 2021 |
| Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy N Dagan, N Barda, T Biron-Shental, M Makov-Assif, C Key, IS Kohane, ... Nature medicine 27 (10), 1693-1695, 2021 | 307 | 2021 |
| Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010–2016 MG Thompson, JC Kwong, AK Regan, MA Katz, SJ Drews, ... Clinical Infectious Diseases 68 (9), 1444-1453, 2019 | 182 | 2019 |
| Developing a COVID-19 mortality risk prediction model when individual-level data are not available N Barda, D Riesel, A Akriv, J Levy, U Finkel, G Yona, D Greenfeld, ... Nature communications 11 (1), 4439, 2020 | 140 | 2020 |
| Effectiveness of BNT162b2 vaccine against delta variant in adolescents BY Reis, N Barda, M Leshchinsky, E Kepten, MA Hernán, M Lipsitch, ... New England Journal of Medicine 385 (22), 2101-2103, 2021 | 104 | 2021 |
| BNT162b2 vaccine effectiveness against omicron in children 5 to 11 years of age CJ Cohen-Stavi, O Magen, N Barda, S Yaron, A Peretz, D Netzer, ... New England Journal of Medicine 387 (3), 227-236, 2022 | 90 | 2022 |
| Automated opportunistic osteoporotic fracture risk assessment using computed tomography scans to aid in FRAX underutilization N Dagan, E Elnekave, N Barda, O Bregman-Amitai, A Bar, M Orlovsky, ... Nature medicine 26 (1), 77-82, 2020 | 77 | 2020 |
| Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting M Mittelman, O Magen, N Barda, N Dagan, HS Oster, A Leader, R Balicer Blood, The Journal of the American Society of Hematology 139 (10), 1439-1451, 2022 | 65 | 2022 |
| Addressing bias in prediction models by improving subpopulation calibration N Barda, G Yona, GN Rothblum, P Greenland, M Leibowitz, R Balicer, ... Journal of the American Medical Informatics Association 28 (3), 549-558, 2021 | 51 | 2021 |
| BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. Reply N Barda, N Dagan, RD Balicer The New England journal of medicine 384 (20), 1970, 2021 | 47 | 2021 |
| Bladder cancer immunotherapy by BCG is associated with a significantly reduced risk of Alzheimer’s disease and Parkinson’s disease D Klinger, BL Hill, N Barda, E Halperin, ON Gofrit, CL Greenblatt, ... Vaccines 9 (5), 491, 2021 | 46 | 2021 |
| Six-month follow-up after a fourth BNT162b2 vaccine dose M Canetti, N Barda, M Gilboa, V Indenbaum, K Asraf, T Gonen, ... New England Journal of Medicine 387 (22), 2092-2094, 2022 | 42 | 2022 |
| Indirect protection of children from SARS-CoV-2 infection through parental vaccination S Hayek, G Shaham, Y Ben-Shlomo, E Kepten, N Dagan, D Nevo, ... Science 375 (6585), 1155-1159, 2022 | 41 | 2022 |
| MHC haplotyping of SARS-CoV-2 patients: HLA subtypes are not associated with the presence and severity of COVID-19 in the Israeli population S Ben Shachar, N Barda, S Manor, S Israeli, N Dagan, S Carmi, R Balicer, ... Journal of Clinical Immunology 41 (6), 1154-1161, 2021 | 41 | 2021 |
| Adverse effects after BNT162b2 vaccine and SARS-CoV-2 infection, according to age and sex N Dagan, N Barda, RD Balicer New England Journal of Medicine 385 (24), 2299-2299, 2021 | 40 | 2021 |
| Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a … G Regev-Yochay, Y Lustig, G Joseph, M Gilboa, N Barda, I Gens, ... The Lancet Microbe 4 (5), e309-e318, 2023 | 29 | 2023 |
